- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00428792
Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)
April 11, 2011 updated by: Novartis
An Open-label, Randomized, Rater-blinded, Cross-over, Multicenter Study Comparing the Clinical Efficacy of Methylphenidate (Immediate Release/Extended Release) Treatment (20 or 40 mg Orally od) in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Under Different Breakfast Conditions Over Two Weeks
This study evaluated the safety and clinical effect of treatment with methylphenidate under different breakfast conditions (minimal breakfast versus standard continental breakfast) in children with Attention-Deficit Hyperactivity Disorder (ADHD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Freiburg, Germany
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 12 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Children aged 6-12
- Diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD)
- Current medication with either 20 mg or 40 mg immediate release methylphenidate
Exclusion Criteria:
- Concomitant psychiatric disorders requiring pharmacological treatment
- Concomitant severe somatic disorders
- Eating disorders
- Addiction disorders
- Very high or low body weight according to age
- Known hypersensitivity to methylphenidate
- Contraindications for methylphenidate
Other protocol-defined inclusion/exclusion criteria applied to the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Very light breakfast (VLB) then standard breakfast (SB)
Very light breakfast (VLB) for one week then crossover to standard breakfast (SB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start.
VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12.
SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12.
|
Other Names:
|
|
Experimental: Standard breakfast (SB) then very light breakfast (VLB)
Standard breakfast (SB) for one week then crossover to very light breakfast (VLB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start.
SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12.
VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Teacher Rating in the Intent-to-Treat (ITT) Population
Time Frame: Friday of each of the 2 treatment weeks
|
The FBB-ADHS is a 20-item rating scale.
Each item describes a typical ADHD symptom.
The 20 items are divided into 3 subscales: Attention deficits (9 items), hyperactivity (7 items), and impulsiveness (4 items).
Each item is rated on a scale of 0 = not at all up to 3 = very much.
The FBB-ADHS was completed by teachers on Friday afternoon of each week of the study.
A total score (sum of all items divided by 20) was calculated.
The total score can range from 0 to 3. A lower score indicates more ADHD.
|
Friday of each of the 2 treatment weeks
|
|
Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Teacher Rating in the Per Protocol (PP) Population
Time Frame: Friday of each of the 2 treatment weeks
|
The FBB-ADHS is a 20-item rating scale.
Each item describes a typical ADHD symptom.
The 20 items are divided into 3 subscales: Attention deficits (9 items), hyperactivity (7 items), and impulsiveness (4 items).
Each item is rated on a scale of 0 = not at all up to 3 = very much.
The FBB-ADHS was completed by teachers on Friday afternoon of each week of the study.
A total score (sum of all items divided by 20) was calculated.
The total score can range from 0 to 3. A lower score indicates more ADHD.
|
Friday of each of the 2 treatment weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Attention Deficit Subscale Teacher Rating
Time Frame: Friday of each of the 2 treatment weeks
|
Teacher rating of the attention deficit subscale (9 items), one of 3 subscales in the FBB-ADHS.
Each item is rated on a scale of 0 = not at all up to 3 = very much.
The rating was completed by teachers on Friday afternoon of each week of the study.
A total score (sum of all items divided by 9) was calculated.
The total score can range from 0 to 3. A lower score indicates more ADHD.
|
Friday of each of the 2 treatment weeks
|
|
Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Hyperactivity Subscale Teacher Rating
Time Frame: Friday of each of the 2 treatment weeks
|
Teacher rating of the hyperactivity subscale (7 items), one of 3 subscales in the FBB-ADHS.
Each item is rated on a scale of 0 = not at all up to 3 = very much.
The rating was completed by teachers on Friday afternoon of each week of the study.
A total score (sum of all items divided by 7) was calculated.
The total score can range from 0 to 3. A lower score indicates more ADHD.
|
Friday of each of the 2 treatment weeks
|
|
Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Impulsiveness Subscale Teacher Rating
Time Frame: Friday of each of the 2 treatment weeks
|
Teacher rating of the hyperactivity subscale (4 items), one of 3 subscales in the FBB-ADHS.
Each item is rated on a scale of 0 = not at all up to 3 = very much.
The rating was completed by teachers on Friday afternoon of each week of the study.
A total score (sum of all items divided by 4) was calculated.
The total score can range from 0 to 3. A lower score indicates more ADHD.
|
Friday of each of the 2 treatment weeks
|
|
Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Parent Rating
Time Frame: Saturday of each of the 2 treatment weeks
|
The FBB-ADHS is a 20-item rating scale.
Each item describes a typical ADHD symptom.
The 20 items are divided into 3 subscales: Attention deficits (9 items), hyperactivity (7 items), and impulsiveness (4 items).
Each item is rated on a scale of 0 = not at all up to 3 = very much.
The FBB-ADHS was completed by teachers on Friday afternoon of each week of the study.
A total score (sum of all items divided by 20) was calculated.
The total score can range from 0 to 3. A lower score indicates more ADHD.
|
Saturday of each of the 2 treatment weeks
|
|
10-Minute Math Test - Problems Attempted
Time Frame: Saturday of each of the 2 treatment weeks
|
The 10-Minute Math Test is a paper and pencil test consisting of several pages of math problems requiring addition, subtraction, multiplication and division calculations presented in ascending order of difficulty during a 10-minute period.
Test difficulty was altered for subjects at different skill levels and ages.
The number of problems attempted is an objective measure related to "academic productivity".
The math test was carried out on the Saturday visit at the end of each of the 2 treatment weeks under supervision of a teacher who had been trained on this test.
|
Saturday of each of the 2 treatment weeks
|
|
10-Minute Math Test - Problems Solved
Time Frame: Saturday of each of the 2 treatment weeks
|
The 10-Minute Math Test is a paper and pencil test consisting of several pages of math problems requiring addition, subtraction, multiplication and division calculations presented in ascending order of difficulty during a 10-minute period.
Test difficulty was altered for subjects at different skill levels and ages.
The number of problems attempted is an objective measure related to "academic productivity".
The math test was carried out on the Saturday visit at the end of each of the 2 treatment weeks under supervision of a teacher who had been trained on this test.
|
Saturday of each of the 2 treatment weeks
|
|
Clinical Global Impression Severity (CGI-S) Scale Score - Physician Rating of Severity
Time Frame: Saturday of each of the 2 treatment weeks
|
The CGI-S is a scale to assess the global severity of illness.
The rating is determined by the investigator answering one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?"
Ratings are on a 7-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.
The rating is based upon the average observed and reported symptoms, behavior, and function in the past 7 days.
|
Saturday of each of the 2 treatment weeks
|
|
Clinical Global Impression (CGI-I) Scale Score - Physician Rating of Improvement (Change in State)
Time Frame: Saturday of each of the 2 treatment weeks
|
The CGI-I is a scale to assess improvement (change in state) of illness.
The rating is based on the investigator answering one question: "Compared to the patient's condition prior to medication, this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."
The investigator compares the patient's overall clinical condition to the 1 week period just prior to the initiation of medication.
|
Saturday of each of the 2 treatment weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Primary Completion (Actual)
December 1, 2007
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
January 29, 2007
First Submitted That Met QC Criteria
January 29, 2007
First Posted (Estimate)
January 30, 2007
Study Record Updates
Last Update Posted (Estimate)
May 6, 2011
Last Update Submitted That Met QC Criteria
April 11, 2011
Last Verified
April 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Disease
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Methylphenidate
Other Study ID Numbers
- CRIT124DDE04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder
-
King's College LondonActive, not recruitingAttention-Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder SymptomsUnited Kingdom
-
Cingulate TherapeuticsSuspendedPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsPremier Research Group plcCompletedADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Qbtech ABEnrolling by invitationAttention Deficit Disorder With Hyperactivity (ADHD) | Attention Deficit Disorder (ADD)United States
-
Universidade do Sul de Santa CatarinaAssociação Brasileira de Cannabis MedicinalRecruitingAttention-Deficit/Hyperactivity Disorder (ADHD)Brazil
-
Nanjing Medical UniversityRecruitingAdult Attention Deficit Hyperactivity DisorderChina
-
Children's Hospital Medical Center, CincinnatiPatient-Centered Outcomes Research Institute; Children's Hospital of Philadelphia and other collaboratorsNot yet recruitingAttention-Deficit/Hyperactivity Disorder (ADHD)United States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAttention Deficit Disorder With HyperactivityUnited States
-
University of Texas at AustinRecruitingAttention Deficit Hyperactivity DisorderUnited States
Clinical Trials on Methylphenidate 20 mg long-acting capsules
-
Rhodes Pharmaceuticals, L.P.CompletedAttention-Deficit/Hyperactivity DisorderUnited States
-
BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
BiogenAbbVie; Friedreich's Ataxia Research AllianceCompletedFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom
-
Tanta UniversityNot yet recruitingCommunity Acquired Pneumonia
-
Monash Medical CentreMonash UniversityRecruiting
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
-
PT Kalbe Farma TbkPT Pharma Metric LabsCompleted
-
Mensia Technologies SAEuropean Union H2020 SME InstrumentUnknownAttention Deficit-Hyperactivity DisorderFrance, Belgium, Germany, Spain, Switzerland
-
Valenta Pharm JSCRecruitingInfluenza | Acute Respiratory Viral InfectionRussia
-
Janssen-Cilag Farmaceutica Ltda.CompletedAttention Deficit Hyperactivity DisorderBrazil